Reported Earnings • 5h
First quarter 2026 earnings released: kr0.045 loss per share (vs kr0.099 loss in 1Q 2025) First quarter 2026 results: kr0.045 loss per share (improved from kr0.099 loss in 1Q 2025). Revenue: kr3.96m (up 17% from 1Q 2025). Net loss: kr2.88m (loss narrowed 51% from 1Q 2025). Over the last 3 years on average, earnings per share has increased by 50% per year but the company’s share price has fallen by 41% per year, which means it is significantly lagging earnings. Reported Earnings • Feb 21
Full year 2025 earnings released: kr0.30 loss per share (vs kr0.46 loss in FY 2024) Full year 2025 results: kr0.30 loss per share (improved from kr0.46 loss in FY 2024). Revenue: kr19.0m (up 122% from FY 2024). Net loss: kr17.6m (loss narrowed 1.0% from FY 2024). Over the last 3 years on average, earnings per share has increased by 44% per year but the company’s share price has fallen by 44% per year, which means it is significantly lagging earnings. New Risk • Feb 04
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Swedish stocks, typically moving 14% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr19m free cash flow). Share price has been highly volatile over the past 3 months (14% average weekly change). Earnings have declined by 7.5% per year over the past 5 years. Market cap is less than US$10m (kr76.6m market cap, or US$8.51m). Minor Risk Revenue is less than US$5m (kr16m revenue, or US$1.8m). Anuncio • Jan 15
aXichem AB Announces Publication of CrossFit Study in Leading Sports Journal - Validates aXivite as a High-Intensity Performance Supplement aXichem AB announced the formal publication of its latest clinical trial, "Acute phenylcapsaicin supplementation improves exercise performance in CrossFit trained adults", in the Journal of the International Society of Sports Nutrition. Following the release of preliminary findings in March 2025, this final peer-reviewed publication provides the definitive scientific foundation for aXivite (phenylcapsaicin) in the elite sports and high-intensity functional fitness sectors. The randomized, triple-blind, placebo-controlled crossover trial, conducted by Dr. Pablo Jiménez Martínez and his team in Spain, examined 50 trained CrossFit athletes (25 male, 25 female). The results demonstrate that a single 2.5 mg dose of aXivite delivers significant physiological advantages: supplemented athletes achieved higher loads and repetition counts in deep squats at 70% 1RM; aXivite enabled participants to maintain weightlifting performance throughout grueling rounds, particularly in the final stages of the workout where fatigue typically peaks; data showed a statistically significant reduction in Delayed-Onset Muscle Soreness at both 24 and 48 hours post-exercise, allowing for faster returns to peak training capacity. This publication marks the latest milestone in a calculated development trajectory. aXichem has systematically built a scientific dossier for aXivite: in 2021, establishing metabolic bioequivalence to natural capsaicin with superior bioavailability and early gut health validation; in 2022-2023, validating metabolic support and weight management, followed by resistance training and aerobic capacity breakthroughs; in 2025, defining the high-intensity performance category through this definitive CrossFit study. Phenylcapsaicin is approved under Novel Food in the EU and GRAS Food in the USA and is marketed for dietary supplements and functional foods under the brand name aXivite. Reported Earnings • Dec 01
Third quarter 2025 earnings released: kr0.052 loss per share (vs kr0.15 loss in 3Q 2024) Third quarter 2025 results: kr0.052 loss per share (improved from kr0.15 loss in 3Q 2024). Revenue: kr4.57m (up kr4.06m from 3Q 2024). Net loss: kr3.07m (loss narrowed 48% from 3Q 2024). Over the last 3 years on average, earnings per share has increased by 40% per year but the company’s share price has fallen by 45% per year, which means it is significantly lagging earnings. Reported Earnings • Aug 31
Second quarter 2025 earnings released: kr0.058 loss per share (vs kr0.032 loss in 2Q 2024) Second quarter 2025 results: kr0.058 loss per share (further deteriorated from kr0.032 loss in 2Q 2024). Revenue: kr6.78m (up 16% from 2Q 2024). Net loss: kr3.41m (loss widened 166% from 2Q 2024). Over the last 3 years on average, earnings per share has increased by 32% per year but the company’s share price has fallen by 37% per year, which means it is significantly lagging earnings. Reported Earnings • May 23
First quarter 2025 earnings released: kr0.099 loss per share (vs kr0.25 loss in 1Q 2024) First quarter 2025 results: kr0.099 loss per share. Revenue: kr3.44m (up 325% from 1Q 2024). Net loss: kr5.88m (loss widened 11% from 1Q 2024). Anuncio • May 17
aXichem AB, Annual General Meeting, Jun 18, 2025 aXichem AB, Annual General Meeting, Jun 18, 2025, at 10:00 W. Europe Standard Time. Location: at the companys offices at sodergatan 26, malmo Sweden New Risk • May 07
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Swedish stocks, typically moving 10.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr18m free cash flow). Earnings have declined by 9.4% per year over the past 5 years. Shareholders have been substantially diluted in the past year (47% increase in shares outstanding). Revenue is less than US$1m (kr8.6m revenue, or US$896k). Market cap is less than US$10m (kr80.7m market cap, or US$8.44m). Minor Risk Share price has been volatile over the past 3 months (10.0% average weekly change). New Risk • Mar 06
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -kr12m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr12m free cash flow). Earnings have declined by 9.4% per year over the past 5 years. Shareholders have been substantially diluted in the past year (175% increase in shares outstanding). Revenue is less than US$1m (kr9.0m revenue, or US$888k). Market cap is less than US$10m (kr76.3m market cap, or US$7.56m). New Risk • Jan 13
New major risk - Financial data availability The company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (14% average weekly change). Shareholders have been substantially diluted in the past year (175% increase in shares outstanding). Market cap is less than US$10m (kr73.3m market cap, or US$6.54m). Reported Earnings • Nov 29
Third quarter 2024 earnings released: kr0.15 loss per share (vs kr0.21 loss in 3Q 2023) Third quarter 2024 results: kr0.15 loss per share. Revenue: kr539.0k (up 88% from 3Q 2023). Net loss: kr5.91m (loss widened 30% from 3Q 2023). Recent Insider Transactions Derivative • Oct 27
CEO & Director exercised options to buy kr942k worth of stock. On the 22nd of October, Torsten Helsing exercised options to buy 700k shares at a strike price of around kr0.95, costing a total of kr665k. This transaction amounted to 1,585% of their direct individual holding at the time of the trade. Since December 2023, Torsten has owned 44.18k shares directly. Company insiders have collectively bought kr697k more than they sold, via options and on-market transactions, in the last 12 months. Reported Earnings • Aug 28
Second quarter 2024 earnings released: kr0.032 loss per share (vs kr0.25 loss in 2Q 2023) Second quarter 2024 results: kr0.032 loss per share (improved from kr0.25 loss in 2Q 2023). Revenue: kr6.13m (up kr5.44m from 2Q 2023). Net loss: kr1.28m (loss narrowed 77% from 2Q 2023). Anuncio • May 23
aXichem AB, Annual General Meeting, Jun 19, 2024 aXichem AB, Annual General Meeting, Jun 19, 2024, at 10:00 W. Europe Standard Time. Location: in the company`s premises, sodergatan 26, malmo Sweden New Risk • Apr 16
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 88% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr21m free cash flow). Share price has been highly volatile over the past 3 months (16% average weekly change). Earnings have declined by 13% per year over the past 5 years. Shareholders have been substantially diluted in the past year (88% increase in shares outstanding). Revenue is less than US$1m (kr1.8m revenue, or US$165k). Market cap is less than US$10m (kr64.7m market cap, or US$5.90m). Anuncio • Mar 28
aXichem AB has completed a Composite Units Offering in the amount of SEK 28.213935 million. aXichem AB has completed a Composite Units Offering in the amount of SEK 28.213935 million.
Security Name: Units
Security Type: Equity/Derivative Unit
Securities Offered: 3,761,858
Price\Range: SEK 7.5
Transaction Features: Rights Offering Anuncio • Mar 13
OmneDiem Launches Two New Products aXichem AB (publ), announced that the provider of dietary supplements OmneDiemis launching two new products, formulated with aXichem's innovative ingredient aXivite, targeting the United States market. These launches represent an expansion of aXivite's applications in the fitness and wellness sectors, underscoring aXichem's commitment to broadening its global market presence and customer base. Body6, a bodybuilding and fitness brand, is set to bring important innovations in the market with the introduction of its Ready-To-Drink (RTD) pre-workout supplement powered by aXichem's aXivite. This innovative product is specifically designed to meet the needs of fitness enthusiasts and bodybuilders, offering an unparalleled boost in performance and energy. Body6 will leverage its partnership with Planet Fitness to make the pre-workout supplement accessible to a wide audience. Additionally, Body6 will feature the pre-workout and its Thermogenic Fat Management product at major national and regional fitness and bodybuilding events, including the prestigious Arnold Classic. OmneDiem is set to introduce a new product in the e-commerce and retail sectors with the launch of MaxRep Elite, a cutting-edge supplement designed to elevate workout performance and endurance. Available through various e-commerce platforms, distributors, retailers, and a network of fitness-oriented health care practitioners, MaxRep Elite aim to become the go-to choice for individuals seeking to maximize their workout potential and achieve their fitness goals. Reported Earnings • Mar 05
Full year 2023 earnings released: kr1.03 loss per share (vs kr1.04 loss in FY 2022) Full year 2023 results: kr1.03 loss per share. Net loss: kr20.8m (loss widened 21% from FY 2022). Reported Earnings • Nov 24
Third quarter 2023 earnings released: kr0.21 loss per share (vs kr0.32 loss in 3Q 2022) Third quarter 2023 results: kr0.21 loss per share (improved from kr0.32 loss in 3Q 2022). Revenue: kr328.0k (up 25% from 3Q 2022). Net loss: kr4.54m (loss narrowed 14% from 3Q 2022). Over the last 3 years on average, earnings per share has fallen by 9% per year but the company’s share price has fallen by 47% per year, which means it is performing significantly worse than earnings. New Risk • Oct 10
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Swedish stocks, typically moving 8.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr27m free cash flow). Earnings have declined by 14% per year over the past 5 years. Revenue is less than US$1m (kr5.0m revenue, or US$465k). Minor Risks Share price has been volatile over the past 3 months (8.8% average weekly change). Shareholders have been diluted in the past year (30% increase in shares outstanding). Market cap is less than US$100m (kr201.2m market cap, or US$18.5m). Reported Earnings • May 25
First quarter 2023 earnings released: kr0.29 loss per share (vs kr0.21 loss in 1Q 2022) First quarter 2023 results: kr0.29 loss per share (further deteriorated from kr0.21 loss in 1Q 2022). Net loss: kr4.76m (loss widened 34% from 1Q 2022). Revenue is forecast to grow 126% p.a. on average during the next 2 years, compared to a 12% growth forecast for the Chemicals industry in Sweden. Over the last 3 years on average, earnings per share has fallen by 11% per year but the company’s share price has fallen by 51% per year, which means it is performing significantly worse than earnings. Reported Earnings • Mar 06
Full year 2022 earnings: EPS and revenues miss analyst expectations Full year 2022 results: kr1.04 loss per share (further deteriorated from kr0.92 loss in FY 2021). Revenue: kr5.22m (up 20% from FY 2021). Net loss: kr17.3m (loss widened 14% from FY 2021). Revenue missed analyst estimates by 17%. Earnings per share (EPS) also missed analyst estimates by 16%. Revenue is forecast to grow 109% p.a. on average during the next 2 years, compared to a 12% growth forecast for the Chemicals industry in Sweden. Over the last 3 years on average, earnings per share has fallen by 10% per year but the company’s share price has fallen by 49% per year, which means it is performing significantly worse than earnings. Anuncio • Feb 07
aXichem AB to Report Fiscal Year 2022 Final Results on May 26, 2023 aXichem AB announced that they will report fiscal year 2022 final results on May 26, 2023 Reported Earnings • Nov 25
Third quarter 2022 earnings released: kr0.32 loss per share (vs kr0.18 loss in 3Q 2021) Third quarter 2022 results: kr0.32 loss per share (further deteriorated from kr0.18 loss in 3Q 2021). Net loss: kr5.25m (loss widened 75% from 3Q 2021). Revenue is forecast to grow 125% p.a. on average during the next 3 years, compared to a 8.1% growth forecast for the Chemicals industry in Sweden. Over the last 3 years on average, earnings per share has fallen by 10% per year but the company’s share price has fallen by 46% per year, which means it is performing significantly worse than earnings. Breakeven Date Change • Nov 16
Forecast to breakeven in 2024 The analyst covering aXichem expects the company to break even for the first time. New forecast suggests the company will make a profit of kr32.0m in 2024. Average annual earnings growth of 113% is required to achieve expected profit on schedule. Reported Earnings • Aug 28
Second quarter 2022 earnings released: kr0.32 loss per share (vs kr0.24 loss in 2Q 2021) Second quarter 2022 results: kr0.32 loss per share (down from kr0.24 loss in 2Q 2021). Revenue: kr702.0k (up kr642.0k from 2Q 2021). Net loss: kr5.20m (loss widened 33% from 2Q 2021). Over the last 3 years on average, earnings per share has fallen by 8% per year but the company’s share price has fallen by 39% per year, which means it is performing significantly worse than earnings. Reported Earnings • May 26
First quarter 2022 earnings released: kr0.21 loss per share (vs kr0.20 loss in 1Q 2021) First quarter 2022 results: kr0.21 loss per share (down from kr0.20 loss in 1Q 2021). Revenue: kr538.0k (up kr486.0k from 1Q 2021). Net loss: kr3.56m (loss widened 13% from 1Q 2021). Over the last 3 years on average, earnings per share has fallen by 8% per year but the company’s share price has fallen by 43% per year, which means it is performing significantly worse than earnings. Board Change • Apr 27
No independent directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 2 highly experienced directors. No independent directors (5 non-independent directors). Chairman of the Board Jan Gustavsson was the last director to join the board, commencing their role in 2017. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment. Reported Earnings • Feb 18
Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat Full year 2021 results: kr0.92 loss per share (down from kr0.85 loss in FY 2020). Net loss: kr15.1m (loss widened 12% from FY 2020). Revenue exceeded analyst estimates by 45%. Over the next year, revenue is forecast to grow 1,027%, compared to a 223% growth forecast for the industry in Sweden. Over the last 3 years on average, earnings per share has fallen by 9% per year but the company’s share price has fallen by 39% per year, which means it is performing significantly worse than earnings. Reported Earnings • May 22
First quarter 2021 earnings released: kr0.20 loss per share (vs kr0.19 loss in 1Q 2020) First quarter 2021 results: Net loss: kr3.15m (loss widened 2.2% from 1Q 2020). Over the last 3 years on average, earnings per share has fallen by 15% per year but the company’s share price has increased by 8% per year, which means it is well ahead of earnings. Is New 90 Day High Low • Feb 18
New 90-day low: kr40.60 The company is down 19% from its price of kr50.40 on 19 November 2020. The Swedish market is up 9.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 18% over the same period. Is New 90 Day High Low • Jan 27
New 90-day low: kr45.70 The company is down 6.0% from its price of kr48.50 on 29 October 2020. The Swedish market is up 18% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 16% over the same period.